Department of Child and Adolescent, University Hospitals of Geneva and Medical School of the University of Geneva, Geneva, Switzerland.
J Allergy Clin Immunol. 2011 Jan;127(1):218-22. doi: 10.1016/j.jaci.2010.08.025. Epub 2010 Oct 28.
Delayed-onset urticarial or maculopapular rashes are frequently observed in children treated with β-lactams. Many are labeled "allergic" without reliable testing.
Determine the etiology of these rashes by exploring both infectious and allergic causes.
Children presenting to the emergency department with delayed-onset urticarial or maculopapular rashes were enrolled. Acute and convalescent sera were obtained for viral screening along with a throat swab. Subjects underwent intradermal and patch skin testing for β-lactams 2 months after presentation. Anti-β-lactam blood allergy tests were also obtained. All subjects underwent an oral challenge test (OCT) with the culprit antibiotic.
Eighty-eight children were enrolled between 2006 and 2008. There were 11 (12.5%) positive intradermal and no positive patch tests. There were 2 (2.3%) positive blood allergy tests. There were 6 (6.8%) subjects with a positive OCT, 2 were intradermal-negative, and 4 were intradermal-positive. No OCT reactions were more severe than the index event. Most subjects had at least 1 positive viral study, 54 (65.9%) in the OCT negative group.
In this situation, β-lactam allergy is clearly overdiagnosed because the skin rash is only rarely reproducible (6.8%) by a subsequent challenge. Viral infections may be an important factor in many of these rashes. OCTs were positive in a minority of intradermal skin test-positive subjects. Patch testing and blood allergy testing provided no useful information. OCTs should be considered in all children who develop a delayed-onset urticarial or maculopapular rash during treatment with a β-lactam.
β-内酰胺类治疗后常出现迟发性荨麻疹或斑丘疹。许多被标记为“过敏”,但缺乏可靠的检测。
通过探索感染和过敏原因,确定这些皮疹的病因。
招募在急诊科就诊的迟发性荨麻疹或斑丘疹患儿。在出现皮疹后 2 个月时,采集急性和恢复期血清进行病毒筛查和咽拭子检查。进行β-内酰胺类皮内和斑贴试验,还进行了抗β-内酰胺血过敏检测。所有患儿均进行了可疑抗生素的口服激发试验(OCT)。
2006 年至 2008 年期间共纳入 88 例患儿。皮内试验 11 例(12.5%)阳性,无斑贴试验阳性。血过敏检测 2 例阳性。OCT 阳性 6 例(6.8%),2 例皮内试验阴性,4 例皮内试验阳性。OCT 反应均未比原发病更严重。大多数患儿至少有 1 项阳性病毒研究,OCT 阴性组中 54 例(65.9%)。
在这种情况下,β-内酰胺过敏明显被过度诊断,因为皮肤皮疹仅在少数情况下(6.8%)通过随后的激发试验重现。病毒感染可能是这些皮疹的重要因素。皮内试验阳性的少数患儿 OCT 阳性。斑贴试验和血过敏检测没有提供有用的信息。OCT 应考虑用于所有在β-内酰胺治疗期间发生迟发性荨麻疹或斑丘疹的患儿。